Mechanistically, AR directly binds AREs within promoter regions of MHC I-associated genes (e.g., HLA-A, B2M, TAP1/2), inhibiting their transcriptional activity and consequently diminishing tumor antigen presentation capacity (55). The gene discussed is AR; the disease is neoplasm.